AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Psychedelicalpha

Published November 6, 2026

FDA Answers House Psychedelics Caucus; ICER to Review Compass' Psilocybin; Terran v ...

Read the full story at Psychedelicalpha

Psychedelics Beyond MAHA? • What ICER's Spravato Review Might Mean for Compass' Psilocybin • Judge Dismisses DemeRx's Ibogaine Suit Against atai,.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics